Ritholtz Wealth Management Acquires 105 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Ritholtz Wealth Management lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 14.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 839 shares of the biotechnology company’s stock after buying an additional 105 shares during the period. Ritholtz Wealth Management’s holdings in United Therapeutics were worth $301,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC boosted its position in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the last quarter. Comerica Bank increased its holdings in United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares in the last quarter. Tri Locum Partners LP bought a new position in United Therapeutics in the second quarter valued at about $15,959,000. Finally, QRG Capital Management Inc. boosted its stake in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after purchasing an additional 1,692 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 0.8 %

United Therapeutics stock opened at $372.81 on Friday. The company has a market capitalization of $16.54 billion, a PE ratio of 17.63, a PEG ratio of 1.30 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $377.03. The firm’s fifty day moving average is $349.90 and its 200 day moving average is $306.93. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.24 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $331.32, for a total transaction of $1,192,752.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $43,071.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $331.32, for a total value of $1,192,752.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $43,071.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,830 shares of company stock worth $36,010,158. Corporate insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Oppenheimer raised their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Finally, TD Cowen upped their price target on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.